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Breast Cancer Screening 1 
Abstract 
 
 Breast cancer is the most common cancer in women. Mammography screening has 
shown improvement in early detection leading to early treatment of breast cancer and thus 
reducing morbidity and mortality rates related to breast cancer. However, the contradictory 
guidelines put forth by the American Cancer Society, American College of Obstetricians and 
Gynecologists, and United States Preventive Services Task Force have posed a compelling 
problem in the health care system, especially for primary care providers: What guideline 
recommendation should be followed? Review of the three sets of guidelines, including the 
systematic reviews from which they were formed, and outside studies were reviewed for further 
information on the benefits and harms of screening mammography. The research results of the 
three guidelines were inconsistent; one set of guidelines did not present stronger evidence than 
another. With the mindset of individualized patient care, a patient education brochure was 
developed as a process to educate patients and have them take an active role in their health 
through engaging in the interactive tool and with their primary care provider, strengthening 
overall patient-primary care provider relationships.  
Introduction 
 
 Over 40,000 people died from breast cancer alone in 2016.1 There were an estimated 
246,660 new cases of breast cancer in women, making breast cancer the most common cancer in 
women, and 2,600 cases of breast cancer in men in 2016. Breast cancer is the second leading 
cause of death related to cancer in women. Age is the most significant risk factor for breast 
cancer.2 Other risk factors include having a first degree relative with a history of breast cancer, 
inherited mutations in BRCA1 and BRCA2 genes, use of menopausal hormone therapy, diabetes 
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mellitus type II, and physical inactivity.1,2 Despite known risk factors, the decrease in breast 
cancer morbidity and mortality has been due to mammography screening in average risk women 
and more aggressive screening in women who pose a higher risk of breast cancer.1  An average 
risk woman is defined as a woman who is physically active without a history of a 1st degree 
relative with breast cancer, no inherited mutations in BRCA1 or BRCA2, has not used 
menopausal hormone therapy, and does not have diabetes mellitus type II. The most common 
symptom of breast cancer is a mass found in the breast, however many individuals present 
asymptomatically. Due to the high incidence of breast cancer, many guidelines have been 
formulated on when to begin screening. There are currently three guidelines widely used in 
clinical practice, but pose a challenge for primary care providers due to the guidelines conflicting 
statements on initiation and frequency of screening.  
 Mammography screening is the most effective tool used for the detection of breast 
cancer. It detects breast cancer at early stages, and in turn, along with the subsequent 
advancement of medical care, breast cancer can be treated more effectively.1 The sensitivity and 
specificity of 2D mammograms in asymptomatic women are 75% and 94.9% respectively.3 
Mortality rates have decreased since the recommendation of regular mammography screening 
has been implemented in standard medical care for women. From 2003 to 2012, there has been a 
1.9% decrease in deaths due to breast cancer.1 Currently, there are three sets of guidelines used 
most frequently in the United States from respected organizations including the American 
College of Obstetricians and Gynecologists (ACOG), American Cancer Society (ACS), and 
United States Preventive Services Task Force (USPSTF). The guidelines have conflicting 
recommendations specifically on when to begin mammography screening in average risk women 
and the frequency of screening. This creates confusion for patients and primary care providers. 
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Many health care systems choose one guideline and have their primary care providers use this as 
the standard of care. For example, Mayo Clinic uses the previously updated American Cancer 
Society guidelines. Table 1 provides a summary of a sampling of health care systems in 
Minnesota and the breast cancer recommendations to which they use as the standard of care. All 
three guidelines advise patients to talk with their primary care providers, thus primary care 
providers must engage in shared decision making, assess dimensions of the decision when to get 
a mammogram, and assist patients in making the best personal decision. 
 With the short amount of time a primary care provider has with a patient during a clinic 
visit, it becomes a challenge for the primary care provider to adequately assess the patient’s risk 
of breast cancer, the patient’s personal values and feelings around mammography, and make an 
informed decision about when to begin screening mammography for each patient. Due to this 
challenge and the differing breast cancer screening guidelines, a literature review was completed 
to assess the strengths and weaknesses of each clinical guideline to best meet the needs for each 
individual patient. A brochure was developed to educate patients on mammography screening 
and the current existing guidelines. The brochure can then be used as a tool for primary care 
providers to begin the conversation about mammography screening decisions. The development 
of the brochure resulted from a review of the formulation of the differing guidelines, associated 
risks and harms of mammography screening, and a patient assessment of personal risk and 
values toward mammograms.  
Background: Literature Review 
 
 In the last two years, 66.8% of women in the United States have chosen to get a 
mammogram imaging screening.4 This percentage increases with age up to age 74, when breast 
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cancer screening guidelines recommend the reduction in frequency of screening. Since the 
development of mammography, this screening modality has become increasingly important as 
the imaging provided from a mammogram is considered the gold standard of care. While 
guidelines encourage patients to be familiar with their body and any changes that occur, clinical 
and self-breast examination have fallen out of favor.1,2,9 This is due in part to unnecessary 
follow-up and procedures most commonly being additional mammography imaging leading to 
possible false results.  Due to the risks and benefits of mammography screening 
 and the increasing prevalence of breast cancer, guidelines have been developed from three 
credible health organizations and revised since mammograms were first introduced into medical 
practice.  
 To begin with, the ACOG guidelines recommend women begin breast cancer 
mammography screening at age 40. The guidelines continue to suggest women should undergo 
screening via mammography imaging yearly. The most recent ACOG recommendations were 
published in 2009. In 2016 these guidelines underwent a systematic review and the evidence 
collected was insignificant and therefore no changes were made.5 Next, the ACS guidelines 
recommend women begin breast cancer mammography screening at age 45. The guidelines 
further recommend that women receive a mammogram every year. These recommendations were 
updated in October of 2015, noting the significant change of the starting age of mammography at 
45 instead of their previous recommendation of age 40.6 The third set of guidelines, USPSTF, 
recommend women begin breast cancer mammography screening at age 50. Unlike the previous 
two guidelines, USPSTF recommends biennial mammography screening.2 Table 2 compares the 
three guidelines including the age to initiate screening and the frequency of screening.   
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 From 2015-2016, each of the guidelines underwent a review. ACS made a major change 
of initiating breast cancer screening mammography at age 45 instead of the previously 
recommended age of 40.7 Each organization completed a systematic review of evidence and 
graded their guidelines. Table 3 summarizes each systematic review including the date, method 
of review, evidence scale, and the changes, if any, that were made to the guidelines.7,8,9 
When considering mammography screening there are many harms but also several 
benefits patients and primary care providers should be aware of. One of the challenges when 
deciding on which guideline to utilize, is weighing out these harms and benefits. A patient 
should be educated on the harms and benefits and work with the primary care provider to make 
an informed patient centered decision. The most significant harms associated with 
mammography screening are the impacts from false negatives, misdiagnosis and over diagnosis. 
False negative results give reassurance of no cancer to a patient when cancer is present. This 
leads to delayed diagnosis, potentially more severe morbidities, and possibly death from breast 
cancer.11 Misdiagnosis and over diagnosis are similar. Misdiagnosis refers to an incorrectly 
classified tumor, meaning it could be a less severe or more severe form of cancer than what the 
patient is diagnosed with.2 Over diagnosis refers to the behavior of the tumor. Perhaps the tumor 
does not progress as expected, such as in ductal carcinoma in situ (DCIS), but was treated as a 
more severe tumor resulting in over treatment of the cancer.2,11 Just as with false negatives, 
results from misdiagnosis and over diagnosis can lead to increased morbidities and mortality that 
may have been otherwise prevented. 
Other potential harms can result from false positives, unnecessary biopsies and follow-
up, and radiation exposure. False positive results are the most common and may be the heaviest 
weighted risk. A false positive result may lead to a higher recall rate and increase the number of 
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unnecessary biopsies.10 Due to the implemented follow-up from a false positive result, increased 
anxiety and psychological harms have also been noted in patients.11 The cumulative risk of a 
false positive increases when mammography is started at a younger age.10 Dense breast tissue is 
also a risk factor for a false positive result. A woman’s breast tissue is denser before menopause, 
and becomes less dense after completion of menopause.12 False biopsies are due to a positive 
mammogram finding and the need to rule in or out cancer. If the biopsy is negative for cancer, 
the biopsy is considered false and thus leading to unnecessary treatment.2 Unnecessary 
treatments not only includes a false biopsy but also women undergoing radiation and 
chemotherapy without ever having breast cancer. Unnecessary biopsies have been reported in 
1.1% of women who had a positive result and underwent a biopsy.13 In addition, there is a small 
amount of ionizing radiation exposure from a mammogram. An average mammogram includes 2 
views of each breast which amounts to 0.4mSv of radiation.6 For comparison, a single view chest 
x-ray is 0.2 mSv and a chest CT is 8.0 mSv.14 Although the radiation is a low amount and 
radiation induced cancer morbidities are uncommon, it is necessary to keep in mind that it is 
possible. It is also important to note patient history of radiation exposure due to other medical 
injuries, illnesses, or occupation that put the patient at an increased risk of radiation induced 
cancer. 
Psychosocial aspects of mammography also need to be considered in all patients. Primary 
care providers should recognize patients’ personal feelings and attitudes toward screening. There 
is some pain and discomfort associated with a mammogram. Although minimal, patients may be 
nervous about it, especially if their pain tolerance is low.15 Anxiety of having a mammogram is 
also common in patients.11 Worry over the results of not only a positive mammogram, but also 
the implications, as previously mentioned, that occur because of a positive test, may increase 
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anxiety about mammography screening. By educating and informing patients on mammograms, 
anxiety could potentially be reduced.  
Although there are many harms that can result from mammography screening, there are 
many benefits that also need to be weighed in the decision making process. The benefits of 
mammography screening are first and foremost, early detection of breast cancer leading to a 
reduction of morbidity and mortality related to breast cancer. Early detection of breast cancer 
includes the detection of DCIS and early, slow growing cancers. DCIS is not likely to develop 
into cancer, but is found with invasive cancer 25% of the time. There is a correlation between the 
size of DCIS and invasion of the associated cancerous tumor; larger lesions have a higher risk of 
invasive cancer.11 The earlier these lesions are detected, the sooner treatment can begin. There is 
potential to remove these lesions before developing into breast cancer through mammography 
screening. Early detections also increase the number of treatment options available to patients for 
treating the breast cancer. Some of these options include mastectomy, chemotherapy, radiation, 
and endocrine therapy. With early detection and effective treatment options, there is a reduced 
number of deaths from breast cancer.2 From 2003 to 2012, breast cancer death rates have 
declined by 1.9% because of early detection via mammogram and thus treatment.1 There is also 
reduced anxiety in patients from not having breast cancer which is a positive factor in patients’ 
overall health and well-being. Another benefit of mammography screening is the establishment 
of a patient relationship with a primary care provider through face to face contact and a 
discussion of mammography screening.16 
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Methods 
 
Initially, each set of guidelines from ACS, ACOG, and USPSTF were reviewed in detail. 
The three guidelines were then compared and contrasted to understand the discrepancies and 
how that could lead to confusion in patients and among primary care providers. The systematic 
reviews of how each guideline was developed were also reviewed. Each systematic review was 
examined in detail to determine how the evidence for each guideline was formed. The grading 
systems were different for each guideline, so it was important to understand and compare 
between the three organizations. Each set of guideline recommendations were based on evidence 
that was found to be statistically significant for each recommendation the individual organization 
put forth.  
The next topic researched was the benefits and harms of mammograms. PubMed was 
used to initiate this search. Key terms including “benefit,” “risk,” “harm,” “outcome,” 
“screening,” and “breast cancer” were used. From initial studies found, each reference section 
was reviewed and subsequent articles were found. Formation of a benefit versus harm risks were 
then compared. More specific searches included mammography screening age for women. Key 
terms such as “frequency,” “age,” and “regularity” were used. The final search was to examine 
patient-primary care provider relationships. The keywords “conversation,” “patient-provider,” 
and “relationship,” and “outcome” were used to find information on the benefit of meeting with a 
primary care provider in discussion of developing a plan for mammography screening.  
When choosing to use an article or not, the type of study was first looked at. Studies that 
were not from peer-reviewed journals were excluded. Studies that included data of 
mammography from the US were included. Studies from Canada were compared against the US 
in the outcomes and guidelines. Canadian health care is similar to the United States, but there 
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were differences in how studies were implemented based on the Canadian health care standards. 
Opinion articles, magazine and media articles were also excluded for bias and inaccurate data 
extraction.  
After collection and review of the research pertaining to ACS, ACOG, and USPSTF 
guidelines, a patient education brochure was created. The purpose of the brochure was educating 
patients on breast cancer and to set a foundation for a conversation to be had between a primary 
care provider and a patient at a preventative health visit. There were two main challenges faced 
when writing the brochure. One challenged posed was to write the brochure in lay language to 
include patients of all education levels and backgrounds. Another challenge was writing in 
gender inclusive language that included consideration for transgender and gender non-
conforming individuals. The brochure was specifically developed for Family Tree Clinic in St. 
Paul, MN. Family Tree Clinic is a non-profit clinic providing reproductive and sexual health 
services. The brochure is intended for patients to look, read, and interact with while in the 
waiting room and therefore be prepared and involved in the conversation with their primary care 
provider about development of a plan for mammography screening.  
Discussion 
 
The first aspect of the brochure was to provide statistics for patients to establish a 
precedence of how relevant breast cancer is in the United States. It also helps to grab patients’ 
attention to the issue and begin thinking about how they would individually like to proceed with 
screening. Next, patient education on mammograms was incorporated. Questions such as ‘What 
is a mammogram?’, ‘What is the purpose of mammography screening?’, and ‘What can be found 
on a mammogram?’ were answered in a clear and concise manner. Next, the three organizations 
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and their corresponding guideline recommendations for starting age and frequency of 
mammography were provided in a table similar to Table 1 found in the appendix.  After the 
guidelines were summarized, a table comparing risks and benefits was created based on the 
research. It was important to have an equal number of risks and benefits to minimize any 
immediate assumptions of more risks or more benefits to mammography screening. Risks 
included in the brochure consisted of a small amount of radiation exposure, a false positive 
including a definition and consequences of a false positive result, false negative results including 
a definition and specificity percentage explained in lay terms, pain and discomfort during a 
mammogram, and increased anxiety of follow-up due to a false positive result. On the contrary, 
benefits of mammograms included in the brochure were early detection of breast cancer, 
mammograms being the best tool for detecting breast cancer, establishment of a patient-primary 
care provider relationship, reduced deaths from breast cancer, and reduced anxiety about breast 
cancer and future mammograms. In total, there were five risks and five benefits included in the 
table. The risks and benefits were listed in the table side by side to make comparison easier for 
patients.   
The front side of the brochure was focused on educating the patient. On the reverse side 
of the brochure, the patient could assess their personal risk and values through answering yes/no 
statements. The first section was assessing if a patient was at average risk for breast cancer. 
There were five statements to assess risk in patients (Figure 1). These questions align with 
known risk factors for breast cancer.  If a patient answer was yes to any of these statements they 
were instructed to discuss their answers with their primary care provider in their appointment as 
they may have an increased risk. The second set of statements assessed a patient’s personal 
feelings and values about mammography screening (Figure 1). The final statement was 
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purposely left as an open-ended statement to address any feelings not addressed in the two 
assessments that the patient has concerns about. Similar to the risk assessment, if a patient 
answer was yes to any of the statements, they were encouraged to further discuss their thoughts 
and feelings toward mammograms with their primary care provider.  
The final portion of the brochure provided a quick link to a risk calculator that asked the 
patient questions and calculated their risk over 5 years. The website portrayed the results in a 
picture format and an easy to understand explanation was also provided. This risk calculator was 
followed by an ending statement and blank space for patients to write down any further questions 
or concerns about mammography screening that they still have. A complete version of the patient 
education brochure can be found in Figure 1 of the appendix. 
Through review of each guideline, there was no statistically significant evidence proving 
or disproving the guideline recommendations. ACS, ACOG, and USPSTF have all completed 
systematic reviews and analyzed significantly statistical evidence in formation of their 
guidelines. The biggest factor noted between the difference in the guidelines is false positive 
results. The consequences from a false positive are significant and numerous. Recalling from the 
literature review section, false positives can result in false biopsies and unnecessary treatment. A 
false positive risk is increased with dense breast tissue and younger start age for screening due to 
an increased number of mammograms during a lifetime. Each organization sets different weight 
to a false positive. For example, ACOG recommends to begin screening at age 40, thus having a 
higher threshold for false positives. From ACOG’s recommendation, it can be implied that they 
are more concerned with the detection of breast cancer than the number of false positives 
received through mammography screening. By beginning mammography screening earlier, there 
is an increased risk of false positives. Consequently, by starting mammography screening later 
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there is an increased risk for missing early breast cancer such as DCIS and detecting a further 
advanced stage breast cancer that could have potentially harsher effects than if detected earlier.  
The heaviest weighted benefit is a reduction in breast cancer morbidity and mortality. 
This reduction is due to the early detection and treatment of breast cancer. A mammogram is the 
most effective tool used to screen for breast cancer. A mammogram has been proven more 
effective than monthly self-examinations and clinical breast exams.2 Mammography screening 
has reduced mortality rates in the United States by 36% from 1989 to 2012.1 The 36% decline is 
equivalent to about 249,000 breast cancer deaths avoided. With the decline in mortality seen over 
the years resulting from the effectiveness of mammography screening in detecting cancer, 
mammograms have changed United States medical practice through the implementation of the 
screening in women over 40 years of age. 
There are potential consequences from having three guidelines to which US health care 
utilizes. Americans are receiving different recommendations depending on which health care 
system they are receiving medical care at. There may also be a difference among primary care 
providers, if their health care employer leaves it up to primary care providers to choose which 
guideline they believe is best to adhere to. As mentioned in the methods section, opinion articles 
were excluded in the writing of this paper, however there were many articles written by primary 
care providers about their opinions on the guidelines, which guideline they prefer, and their 
thoughts about the changes in the guidelines, such as the starting age adjustment from 40 to 45 in 
the ACS guidelines, to which there is a strong debate between primary care providers.  
Through thorough research into each guideline and its’ recommendations and the 
formation of a patient education brochure, a primary care provider is adequately prepared to 
discuss breast cancer screening mammography with patients. By having the patient read and 
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actively participate in the brochure, it will hopefully encourage discussion from the patient 
perspective. To begin the conversation, the primary care provider would sit down with their 
patient and briefly go through the brochure to assess patient risk-level for breast cancer, 
understanding of breast cancer mammography screening, and personal values around screening. 
Specifically, they should assess understanding of the differing guidelines and the risks and 
benefits associated with mammography. 
Once the primary care provider is satisfied with patient comprehension, the conversation 
can continue in discussion of the two assessment sections. The first section, assessing risk, will 
help the primary care provider to decipher out any concerning risk factors, or red flags, the 
patient may have for breast cancer. Next, the primary care provider can address the patients’ 
feelings and values toward mammography. At this time in the conversation, the primary care 
provider will have established a good rapport with the patient, encouraging the patient to trust 
and feel comfortable talking about their feelings formed from the information they have received 
via the patient education brochure. The primary care provider can address any misconceptions or 
concerns the patient may have. The primary care provider will then address any further questions 
the patient has written down or that have been provoked throughout the current conversation. 
Meaningful conversation has taken place, and the patient and primary care provider can make a 
shared and well-informed decision that is individualized to the patient circumstance about when 
to begin mammography screening.  
Conclusion 
 
The ACS, ACOG, and USPSTF have contradictory breast cancer screening guidelines, 
but each is currently used in United States health care. There is not one guideline 
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recommendation that is significantly better or worse than the other. The factors, including harms 
and benefits, are weighted differently in each guideline, resulting in the differing 
recommendations on mammography screening. Patient education and individualization is vital in 
determining which guideline fits each patient presentation. It is important for primary care 
providers to stay up to date on changes made to the guidelines.  
All health care decisions should be made with the patient’s best interest in mind. The 
patient-centered brochure is a tool with the potential for utilization by all patients. It was 
developed to be inclusive for use with transgender and gender non-conforming patients, and can 
set a foundation of knowledge that prepares a patient for a conversation with their primary care 
provider about mammography screening. The tool is also interactive, including assessment 
statements to answer as well as a risk calculator to calculate a numerical personal risk, giving the 
patient the confidence to take control of their health decision making.  
Although there cannot be direct statements drawn from the review of each of the three 
guidelines, preferences toward guidelines are seen. For example, health care systems, such as 
Mayo Clinic have their primary care providers abide to the recommendation of beginning 
mammography screening at age 40. Other health care systems including Allina Health System 
and Fairview Health System suggest having a plan in place by the time a patient is 40 years old. 
Some health systems take a hybrid approach and incorporate numerous sections of the guidelines 
into their own guidelines. It is also important to note that the guidelines are always changing. As 
new studies are completed and analyzed, the guidelines may change in one direction or the other.  
One note of importance is ACOG used ACS guidelines as a strong factor in their 
systematic review in formulation of their guidelines. ACS updated their guidelines and made the 
monumental change of recommending starting age of mammography screening to be 45 years 
Breast Cancer Screening 15 
old. The review completed by ACOG was done in early 2015 before ACS published their 
updated guidelines later in 2015. Because of ACOG’s reliance and use of ACS guidelines in their 
systematic review, a change in their guidelines may be possible in the coming years as they 
reassess breast cancer mammography screening start age.  
Another topic briefly mentioned, but not covered in detail in the paper and patient 
brochure is the frequency to which mammography screening should be completed. There are the 
same risks and benefits that are weighed out in this choice as there were in when to begin 
mammography screening. More research should be completed to determine whether a woman 
should have a mammogram yearly or biennially. Although there are differing guidelines, a broad 
statement can be made that in younger screening, women age 40-55, yearly screening is 
generally accepted. After the age of 55, women can choose to get mammograms every other 
year. Although there is slight discrepancy between the health organization guidelines, this 
general recommendation is a combination of the three guidelines. This factor of mammogram 
frequency is difficult to study due to the length of time a study would need to be conducted to 
determine outcomes of mammography screening frequency. Due to the length of time, there is 
also a large associated cost.  
Further research could be conducted in looking at current patient education tools. There 
are many online tools that calculate an individual’s 5-year, 10-year, and lifetime risk using the 
Gail model. Most clinics have educational materials on mammography screening, but Family 
Tree Clinic is unique in that it strives for individualized patient decisions. Future studies could 
include patient satisfaction and an assessment of knowledge gained through the brochure.  
This research is applicable to family medicine practice and specifically to women’s 
health medical practice. The three guidelines, ACS, ACOG, and USPSTF, are used and respected 
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in United States health care today. With the three guidelines having conflicting views, it creates 
some confusion for patients and primary care providers. This could have a potential detrimental 
impact on mammography screening and overall women’s health. Mammography screening is a 
vital aspect of women’s health and wellness. It is important for primary care providers to take the 
time to sit down with each patient to develop an individualized and shared patient-primary care 
provider decision in when to begin mammography screening for breast cancer. 
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Appendix 
 
Table 1. Use of recommendations from ACS, ACOG, and USPSTF guidelines on breast cancer 
screening. 
Health Primary care providers in 
Minnesota 
Position on breast cancer screening 
Mayo Clinic Begin yearly mammograms at age 40 
Fairview Health System Develop a plan by age 40, starting yearly 
mammograms no later than age 50 
Health Partners Begin to discuss a plan at age 40 
Park Nicollet Begin yearly mammograms at age 40 
Allina Health System Talk with primary care provider 
 
 
Table 2. Breast cancer guideline recommendations for mammography screening.  
 US Preventive 
Services Task Force 
American Cancer 
Society 
American College of 
Obstetricians and 
Gynecologists 
Starting Age 50 45 40 
Frequency Biennial Yearly Yearly 
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Table 3. Systematic review summary of ACOG, ACS, and USPSTF guidelines. 
Guideline Last 
reviewed/updated 
Methods of data 
collection/analysis 
Evidence Scale Changes to 
guidelines 
ACOG8 2016 • 2 independent 
reviewers 
• Key questions 
to focus 
evidence 
• Poor, fair, 
good 
• Guidelines: 
not graded 
 
No changes 
made to 
guidelines 
ACS7 October 2015 • 2 independent 
reviewers 
• Statistical 
analysis of data 
• High, 
moderate, 
low, very 
lowa 
• Guidelines: 
strong or 
qualifiedb 
Yes: beginning 
age of 
mammography 
from 40 to 45 
years old 
USPSTF9 April 2015 • 2 independent 
reviewers 
• Key questions 
• Key 
questions: 
good, fair or 
poor 
• Guidelines: 
A, B, C, D, 
or Ic 
No changes 
made to 2009 
guidelines 
a A high recommendation meant the reviewers were very confident the true effect was close to 
the estimated effect.  Very low recommendation meant the reviewers had little confidence in the 
effectiveness estimate 
b A strong recommendation is one most patients should receive whereas a qualified 
recommendation means the majority of patients would want the recommendation, but many 
would not.  
c “A” means the benefit of the guideline was substantial and effectiveness decreases with letter 
grade; “D” instituting a negative effect. A grade of “I” meant the evidence was insufficient and 
thus could not be awarded a letter grade.  
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Figure 1. Patient education brochure information. 
Mammography Screening 
Breast/chest Cancer Statistics 
• 1 in 8 people assigned female at birth are diagnosed with breast/chest cancer in their 
lifetime.1 
• 8 in 1 million people assigned male at birth are diagnosed with breast/chest cancer in 
2016.2 
• Breast/chest cancer is the most common cancer in people assigned female at birth.2 
• Breast/chest cancer is the second leading cause of death among people assigned female 
at birth2.  
• Over 2.8 million breast/chest cancer survivors are alive in the United States today.2 
What is a mammography screening? 
 A screening mammogram is an x-ray of breast/chest tissue that looks for breast/chest 
cancer in people assigned female at birth without any signs or symptoms present.  
What is the purpose of getting a mammogram? 
  To detect and diagnose breast/chest cancer at an early stage. At an early state, 
breast/chest cancer is easier to treat in order to reduce chance of disease related to breast/chest 
cancer and to reduce deaths from breast/chest cancer.  
What can be found on a mammogram? 
 A mass of breast/chest tissue that is abnormal compared to normal breast/chest tissue. 
The mass can be benign (non-cancerous) or malignant (cancerous). 
Mammogram recommendations 
 US Preventive 
Service Task Force 
American Cancer 
Society 
American College of 
Obstetricians and 
Gynecologists 
Starting Age 50 45 40 
Frequency Every two years Every year Every year 
 
Benefits and Risks of mammograms 
Benefits Risks 
Early detection of breast/chest cancer Small amount of radiation exposure from a 
mammogram 
Mammograms are best tool for detecting 
breast/chest cancer 
False-positive (a mass that is thought to be 
cancerous turns out to be non-cancerous) can 
lead to unnecessary treatment 
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Establishing a relationship with a primary care 
provider in discussing mammograms 
False-negative (mammogram does not detect a 
cancerous mass) – mammograms find 
breast/chest cancer 75% of the time3 
Reduced deaths from breast/chest cancer Pain and discomfort during exam (from the 
mammogram machine) 
Can reduced anxiety about breast/chest cancer 
and future mammograms 
Increased anxiety if false-positive results 
 
When should I start getting a mammogram? 
Here are some questions that may help you and your health care provider decide when to 
start mammography screening for breast/chest cancer:  
Assessing your risk: mark yes or no to the statements below. 
1. I have a parent, sibling, or child who has been diagnosed with breast/chest cancer. 
Yes/No 
2. I am 50 years of age or older and have never had a mammogram. Yes/No 
3. I have had previous radiation to my chest related to another cancer. Yes/No 
4. I have used menopausal hormone therapy. Yes/No 
5. I have been told I have BRCA1 or BRCA2 gene. Yes/No 
If you have answered yes to any of the above statements, you may have an increased risk of 
breast/chest cancer and should discuss your answers with your health care provider.  
Assessing your personal feelings and values about mammography screening: mark yes or 
no to the statements below. 
1. I want a mammogram. Yes/No 
2. I am worried about the cost of the mammogram. Yes/No  
3. I am worried about experiencing pain or discomfort during a mammogram. Yes/No 
4. I am worried about a potential positive result from a mammogram. Yes/No 
5. I am worried about radiation exposure from a mammogram. Yes/No 
6. Other feelings I have toward mammograms are: _________________________________ 
If you have answered yes to any of the above statements, you should talk with your health 
care provider about your preferences and feelings toward mammography screenings. 
By accessing the following website, you can calculate your present risk of breast/chest 
cancer:  
http://breastscreeningdecisions.com/#/info 
Please include any questions or concerns you have about mammography screening:  
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
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Resources for current statistics: 
1 Breast Cancer Research Foundation 
2 American Cancer Society – Cancer Facts and Figures 2016 
3Kavanagh AM, Giles CG, Mitchell H, et al. The sensitivity, specificity, and positive 
predictive value of screening mammography and symptomatic status. J Med Screen. 
2007;7(2):105-110.  
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